Missed GME or NVDA? Donโt Miss the Next One.โ
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
GDTC Stock Forecast 2025-2026
$2.35
Current Price
$26.89M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GDTC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
GDTC Price Momentum
+5.9%
1 Week Change
+0.9%
1 Month Change
+10.8%
1 Year Change
-30.9%
Year-to-Date Change
-42.0%
From 52W High of $4.05
+95.8%
From 52W Low of $1.20
๐ MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching CytoMed (GDTC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on GDTC and similar high-potential opportunities.
Latest GDTC Stock Price Targets & Analyst Predictions
GDTC has shown a year-to-date change of -30.9% and a 1-year change of 10.8%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for GDTC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GDTC Analyst Ratings
1
Buy
0
Hold
0
Sell
GDTC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.35
Latest GDTC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GDTC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 10, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $5.00 |
| Jun 11, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $5.00 |
| Dec 4, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $5.00 |
| Jul 21, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Initiates | $5.00 |
Cytomed Therapeutics Ltd. (GDTC) Competitors
The following stocks are similar to CytoMed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cytomed Therapeutics Ltd. (GDTC) Financial Data
Cytomed Therapeutics Ltd. has a market capitalization of $26.89M with a P/E ratio of 0.0x. The company generates $387,698 in trailing twelve-month revenue with a 75.4% profit margin.
Revenue growth is +24.9% quarter-over-quarter, while maintaining an operating margin of -530.3% and return on equity of -24.9%.
Valuation Metrics
Market Cap
$26.89M
Enterprise Value
$17.48M
P/E Ratio
0.0x
PEG Ratio
-15.5x
Price/Sales
53.4x
Growth & Margins
Revenue Growth (YoY)
+24.9%
Gross Margin
N/A
Operating Margin
-530.3%
Net Margin
+75.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+18.3%
Current Ratio
9.9x
Debt/Equity
5.1x
ROE
-24.9%
ROA
-17.4%
๐ฐ DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cytomed Therapeutics Ltd. (GDTC) Business Model
About Cytomed Therapeutics Ltd.
What They Do
Develops innovative medical therapies for rare diseases.
Business Model
The company operates by researching and commercializing novel therapies, focusing on unmet medical needs. It generates revenue through partnerships with academic institutions and healthcare providers, aiming to advance its drug development pipeline and bring effective treatments to market.
Additional Information
Cytomed is positioned as a key player in the biotechnology and pharmaceutical sectors, with potential for significant market impact due to its focus on groundbreaking medical advancements. Its success in clinical trials and regulatory approvals is critical for enhancing its market position and attracting investor interest.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
43
CEO
Dr. Wee Kiat Tan Ph.D.
Country
Singapore
IPO Year
2023
Website
w2.cytomed.sgCytomed Therapeutics Ltd. (GDTC) Latest News & Analysis
Latest News
Quick Summary
CytoMed Therapeutics (NASDAQ: GDTC) reported its full-year financial results for 2024, focusing on donor-derived immunotherapies. The company does not engage in contract manufacturing or diagnostics.
Why It Matters
CytoMed's financial results and updates on its proprietary immunotherapy technologies could influence stock performance, impacting investor sentiment and future growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CytoMed Therapeutics (NASDAQ: GDTC) announced a letter to shareholders from the Chairman ahead of its full-year audited results, expected by the end of April 2025.
Why It Matters
CytoMed's upcoming full-year results can significantly impact share price and investor sentiment, indicating financial health and future growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor
4 months ago
Quick Summary
CytoMed Therapeutics GDTC stock decreased by 6.35%, trading at $3.23 as of the latest update on Monday.
Why It Matters
CytoMed Therapeutics' stock decline signals potential concerns about company performance or market sentiment, impacting investor confidence and future investment decisions.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
The 74th Emerging Growth Conference will be held on August 21-22, 2024, as announced by EmergingGrowth.com, a prominent small cap media portal.
Why It Matters
The Emerging Growth Conference showcases small-cap opportunities, potentially influencing investor interest and stock performance in emerging companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CytoMed has been granted another patent for its allogeneic iPSC-derived hybrid gamma delta natural killer T cells technology, enhancing its intellectual property portfolio.
Why It Matters
The patent enhances CytoMed's competitive edge in innovative cancer therapies, potentially increasing its market value and attracting investment in the biotechnology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CytoMed Therapeutics (NASDAQ:GDTC) has entered a research collaboration with Sengkang General Hospital in Singapore to develop allogeneic cell-based immunotherapies for cancer treatment.
Why It Matters
The collaboration may enhance CytoMed's research capabilities and credibility, potentially leading to breakthroughs in cancer treatments, influencing stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About GDTC Stock
What is Cytomed Therapeutics Ltd.'s (GDTC) stock forecast for 2025?
Analyst forecasts for Cytomed Therapeutics Ltd. (GDTC) are not currently available. The stock is trading at $2.35.
Is GDTC stock a good investment in 2025?
According to current analyst ratings, GDTC has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GDTC stock?
Price predictions from Wall Street analysts for GDTC are not currently available. The stock is trading at $2.35.
What is Cytomed Therapeutics Ltd.'s business model?
The company operates by researching and commercializing novel therapies, focusing on unmet medical needs. It generates revenue through partnerships with academic institutions and healthcare providers, aiming to advance its drug development pipeline and bring effective treatments to market.
What is the highest forecasted price for GDTC Cytomed Therapeutics Ltd.?
Price targets from Wall Street analysts for GDTC are not currently available. The stock is trading at $2.35.
What is the lowest forecasted price for GDTC Cytomed Therapeutics Ltd.?
Price targets from Wall Street analysts for GDTC are not currently available. The stock is trading at $2.35.
What is the overall GDTC consensus from analysts for Cytomed Therapeutics Ltd.?
The overall analyst consensus for GDTC is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are GDTC stock price projections?
Stock price projections, including those for Cytomed Therapeutics Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 12:10 AM UTC